New hope for rare cancers: immunotherapy combo trial launches
NCT ID NCT06790706
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 24 times
Summary
This study tests a combination of two immunotherapy drugs (domvanalimab and zimberelimab) in people with five types of rare advanced cancers that have not responded to standard treatment. The goal is to see if this treatment can control the cancer for at least 24 weeks. About 154 participants will be treated at 15 centers in France.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AP-HM, TIMONE Hospital, medical oncology department
NOT_YET_RECRUITINGMarseille, 13009, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
AP-HP, Tenon Hospital, medical oncology department
NOT_YET_RECRUITINGParis, 75020, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Centre Eugène Marquis, medical oncology department
NOT_YET_RECRUITINGRennes, 35042, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Centre Hospitalier Universitaire de Lille, medical oncology department
NOT_YET_RECRUITINGLille, 59037, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hospices Civils de Lyon, Medical Oncology Department, Edouard Herriot Hospital
RECRUITINGLyon, 69003, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hospices Civils de Lyon, Medical Oncology Department, Lyon SUD Hospital
RECRUITINGPierre-Bénite, 69310, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hospices Civils de Lyon, Thoracic Oncology Department, Louis Pradel Hospital
RECRUITINGBron, 69500, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Insitut de Cancérologie Strasbourg Europe, medical oncology department
NOT_YET_RECRUITINGStrasbourg, 67200, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Institut Bergonié, medical oncology department
NOT_YET_RECRUITINGBordeaux, 33076, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Institut Curie, thoracic oncology department
NOT_YET_RECRUITINGParis, 75005, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Institut Gustave Roussy, medical oncology department
NOT_YET_RECRUITINGVillejuif, 94805, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Institut Paoli-Calmettes Marseille, medical oncology department
NOT_YET_RECRUITINGMarseille, 13009, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Institut Régional du Cancer de Montpellier, medical oncology department
NOT_YET_RECRUITINGMontpellier, 34298, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Institut de Cancerologie de l'Ouest , medical oncology department
NOT_YET_RECRUITINGAngers, 49055, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
ONCOPOLE Claudius Regaud, IUCT-Oncopole, medical oncology department
NOT_YET_RECRUITINGToulouse, 31059, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.